Cipepofol

Cipepofol
Clinical data
Trade namesCypsedo
Other namesCiprofol; CS-0064163; CS0064163; GTPL10812; GTPL-10812; HSK-3486; HSK3486; HY-116152; HY116152; (R)-2-(1-Cyclopropylethyl)-6-isopropylphenol
AHFS/Drugs.comcypsedo
License data
Routes of
administration
Intravenous infusion
Drug classGABAA receptor positive allosteric modulator
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver glucuronidation
ExcretionKidney
Identifiers
  • 2-[(1R)-1-cyclopropylethyl]-6-propan-2-ylphenol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC14H20O
Molar mass204.313 g·mol−1
3D model (JSmol)
  • C[C@H](C1CC1)C2=CC=CC(=C2O)C(C)C
  • InChI=1S/C14H20O/c1-9(2)12-5-4-6-13(14(12)15)10(3)11-7-8-11/h4-6,9-11,15H,7-8H2,1-3H3/t10-/m1/s1
  • Key:BMEARIQHWSVDBS-SNVBAGLBSA-N

Cipepofol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known as ciprofol or by its developmental code name HSK3486, sold under the brand name Cypsedo, is a general anesthetic related to propofol which is used for anesthesia and sedation. The drug is used by intravenous infusion. A short-acting and highly selective GABAA positive allosteric modulator, ciprofol is 4 to 6 times more potent than other phenol derivatives such as propofol or fospropofol.

In May 2026, cipepofol was approved by the US FDA. Manufactured by Haisco Pharmaceutical Group of Chengdu, Sichuan, China, ciprofol underwent phase I and II trials in Australia and China. In these early studies, ciprofol was comparable in efficacy to propofol and was associated with fewer adverse events.